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Introduction: The use of hematopoietic cell transplantation (HCT) has previously been shown to ameliorate cutaneous
blistering in pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), an inherited skin disorder that
results from loss-of-function mutations in COL7A1 and manifests as deficient or absent type VII collagen protein (C7)
within the epidermal basement membrane. Mesenchymal stem cells (MSCs) found within the HCT graft are believed to
be partially responsible for this amelioration, in part due to their intrinsic immunomodulatory and trophic properties
and also because they have been shown to restore C7 protein following intradermal injections in models of RDEB.
However, MSCs have not yet been demonstrated to improve disease severity as a stand-alone systemic infusion
therapy. Improving the efficacy and functional utility of MSCs via a pre-transplant conditioning regimen may bring
systemic MSC infusions closer to clinical practice.
Methods: MSCs were isolated from 2- to 4-week-old mice and treated with varying concentrations of transforming
growth factor-β (TGFβ; 5-20 ng/mL), tumor necrosis factor- α (TNFα; 10-40 ng/mL), and stromal cell-derived factor 1-α
(SDF-1α; 30 ng/mL) for 24-72 hours.
Results: We demonstrate that treating murine MSCs with exogenous TGFβ (15 ng/mL) and TNFα (30 ng/mL) for 48 hours
induces an 8-fold increase in Col7a1 expression and a significant increase in secretion of C7 protein, and that the effects
of these cytokines are both time and concentration dependent. This cytokine treatment also promotes a 4-fold increase
in Tsg-6 expression, a gene whose product is associated with improved wound-healing and immunosuppressive features.
Finally, the addition of exogenous SDF-1α to this regimen induces a simultaneous upregulation of Col7a1, Tsg-6, and Cxcr4
expression.
Conclusions: These data suggest that preconditioning represents a feasible method for improving the functional utility
of MSCs in the context of RDEB stem cell transplantation, and also highlight the applicability of preconditioning principles
toward other cell-based therapies aimed at treating RDEB patients.Introduction
Epidermolysis bullosa represents a spectrum of blistering
diseases that vary in genetic etiology, molecular phenotype,
and clinical severity [1]. Of the major epidermolysis bullosa
subtypes, one of the most profound in terms of clinical
presentation and progression is recessive dystrophic epider-
molysis bullosa (RDEB). RDEB is characterized by loss-of-
function mutations within the collagen type VII gene* Correspondence: tolar003@umn.edu
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of type VII collagen protein (C7) within the dermal–epider-
mal junction (DEJ) [2,3]. Normally, C7 is synthesized and
secreted as procollagen homotrimers by keratinocytes and
dermal fibroblasts, and further processed and assembled
within the extracellular space into anti-parallel dimers,
which polymerize into anchoring fibrils [3,4]. Anchoring fi-
brils provide a structural attachment between the epidermal
basement membrane and papillary dermis, thus strengthen-
ing the DEJ [5]. In RDEB, however, the diminished presence
of functional C7 precludes DEJ integrity and results in the
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proaching RDEB therapy, including genetic correction
of RDEB cells [6-9], intradermal injection of allogeneic
fibroblasts [10,11], as well as intradermal [12,13] and
systemic [14] injection of recombinant C7. While intra-
dermal fibroblast injections have been shown to im-
prove wound healing in selected areas of ulcerated
human RDEB skin, the remaining techniques have yet
to be tested in RDEB patients, and none have looked at
systemic responses in these populations. In contrast, the
use of hematopoietic cell transplantation (HCT) has
been demonstrated to promote systemic wound healing
and to ameliorate the disease phenotype in pediatric
RDEB patients [15,16]. Specifically, healthy allogeneic
donor cells contained within the hematopoietic graft are
capable of homing to the site of mucocutaneous injury,
engrafting, and promoting repair at wounded recipient
tissue sites [17]. However, taking into consideration that
RDEB patients are already hypersensitive to infections
due to the loss of mucocutaneous barriers, the immuno-
myeloablative conditioning regimens required for trans-
plantation may exacerbate these predispositions while
also introducing additional risks [16].
Reducing the degree of immunomyeloablative condi-
tioning used for transplantation must be weighed against
the patient’s likelihood of developing graft-versus-host dis-
ease, a major immune complication associated with HCT.
A potential solution to this balancing act involves the use
of nonhematopoietic mesenchymal stem cells (MSCs),
which not only exhibit local immunosuppressive proper-
ties [18,19] but also serve as secretory sources for adhesive
molecules, anti-apoptotic and anti-fibrotic growth factors
at injured tissue, and other bioactive molecules that sup-
port local progenitor cells [20-22]. The co-administration
of MSCs within HCT protocols has previously been
shown to promote hematopoietic engraftment in the set-
tings of hematologic malignancy [23] and recovery from
breast cancer chemotherapy [24], while infusions of MSCs
alone have shown additive benefit relative to HCT in the
context of osteogenesis imperfecta [25]. Additionally,
while the exact mechanisms involved in HCT-mediated
amelioration of RDEB are not completely understood, it is
thought that nonhematopoietic cells within the graft, in-
cluding MSCs, may be largely responsible [17].
The potential role for MSCs in RDEB therapy was most
recently supported by Alexeev and colleagues [26], who used
a Col7a1–/– mouse model to demonstrate that intradermal
injections of wild-type MSCs could partially restore the
basement membrane by increasing local C7 expression to
15% that of wild-type mice. However, we previously found
that the use of wild-type MSCs as a stand-alone systemic in-
fusion therapy was insufficient to rescue Col7a1–/– mice
from their typical early death, despite the ability of wild-type
MSCs to express Col7a1 mRNA, albeit at relatively lowlevels [27]. While these shortcomings may in part be due to
the current inefficiencies of systemic MSC infusions, they
are also confounded by the very short lifespan (2 to 3 days)
of RDEB pups. Additionally, within murine RDEB models,
simply increasing the number of transplanted MSCs to en-
hance cumulative C7 expression potentiates the odds of
infusional toxicity, where entrapment of donor cells in pul-
monary capillaries and/or peripheral organs results in recipi-
ent dysfunction. Thus, although intradermal injection of
MSCs throughout affected body surfaces of RDEB patients
would be an arduous process, the previous results from
Alexeev and colleagues [26] provide evidence that if sys-
temic infusions of MSCs are able to reach cutaneous areas
in sufficient quantities, restoration of basement membrane
integrity is a realistic outcome.
It may be possible to improve the efficacy and safety of
allogeneic infusion protocols in the context of RDEB by
utilizing a combined approach in which MSC migration to
wounded tissue is enhanced and their transcription of
COL7A1 is upregulated, thereby increasing cumulative C7
secretion within recipient tissue. In theory, this could allow
for a reduced immunomyeloablative conditioning regimen
by taking advantage of the immunosuppressive properties of
MSCs, while also promoting an increased functional utility
for MSCs via increased COL7A1 transcription.
With regards to an enhanced migratory capacity for
MSCs, the CXCR4/stromal cell-derived factor 1-alpha
(SDF-1α) axis, an interaction classically attributed to
lymphocyte homing and development, has also been impli-
cated in the recruitment of transplanted cells to injured
tissue. Studies examining potential stem cell therapies for
spinal cord injury [28] and myocardial infarction [29] have
demonstrated the importance of the CXCR4/SDF-1α axis
in this recruitment process. Furthermore, Jones and col-
leagues demonstrated that treating human fetal MSCs with
SDF-1α in vitro resulted in a significant upregulation of
CXCR4 transcription, as well as an increase in the number
of cell surface CXCR4+ cells [30]. This strategy led to im-
proved transplantation outcomes in a model of osteogen-
esis imperfecta, and holds promise as a technique to
improve the number of exogenous MSCs recruited to in-
jured tissue in various disease models.
Furthermore, a prime example of how the immuno-
suppressive properties of MSCs can coincide with their
ability to improve wound healing is demonstrated by
tumor necrosis factor alpha (TNFα)-stimulated protein
6 (TSG-6). Expression of TSG-6 by MSCs has been as-
sociated with both improved wound healing and down-
regulation of macrophage proinflammatory signals at
wounded tissue sites [31]. The role of TSG-6 in trans-
planted MSCs has also been highlighted by its anti-
inflammatory properties and its ability to reduce infarct
sizes in a model of myocardial infarction [32]. Trans-
plantation therapies with the goal of healing wounded
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thus potentially benefit from increasing the degree of TSG-
6 expression within the population of transplanted cells.
Lastly, previous studies have demonstrated the feasibility
of upregulating COL7A1 transcription in fibroblasts [33,34]
and keratinocytes [35] by incubating cells in the presence
of cytokines such as TNFα and transforming growth factor
beta (TGFβ). The upregulatory function that TGFβ has on
COL7A1 expression has been characterized previously
[36,37]. Additionally, Knaup and colleagues found that ex-
pression of COL7A1 in the RDEB cell lines was increased
and attributable to elevated TGFβ levels in the local envir-
onment [38]. However, it remains to be seen whether these
findings can be applied to MSCs; that is, whether MSCs
can be induced to upregulate COL7A1 expression, and fur-
thermore whether increased COL7A1 expression can be
coupled with enhanced MSC migration and immunosup-
pression as a model for improved transplantation efficacy
in RDEB. In the present study, we demonstrate that an
in vitro cytokine preconditioning protocol can simultan-
eously upregulate Cxcr4, Tsg-6 and Col7a1 expression
within murine MSCs. We also evaluate whether this ap-
proach can serve as a realistic addition to current stem cell
infusion protocols aimed at treating RDEB patients.
Materials and methods
Isolation and culture of murine mesenchymal stem cells
MSCs were extracted from compact bone of healthy mice
between the ages of 2 and 3 weeks using the protocol and
characterizations described by Zhu and colleagues [39]. Cells
were cultured in alpha minimum essential medium
(αMEM) +10% fetal bovine serum +100 U/ml penicillin/
streptomycin. Culture medium was changed every 2 or 3
days, and plastic-adherent cells were passaged at 70 to 80%
confluence using 0.25% trypsin–ethylenediamine tetraacetic
acid. Cells from passages 2 to 4 were used in all experiments.
All animal studies were approved by the University of Min-
nesota Institutional Animal Care and Use Committee.
Reagents
Ligands, cytokines, and antagonists used within the precon-
ditioning protocol and related experiments were purchased
from R&D Systems (Minneapolis, MN, USA): recombinant
mouse CXCL12/SDF-1α, recombinant mouse TGFβ2, re-
combinant mouse TNFα, and AMD3100.
RNA extraction, reverse transcription, and quantitative
polymerase chain reaction
RNA was extracted using an RNeasy Mini Kit and RNase-
Free DNase Set (Qiagen, Venlo, the Netherlands) according
to the manufacturer’s protocol. RNA concentrations were
quantified using a NanoDrop system (Thermo Fisher Scien-
tific, Waltham, MA, USA). All samples used in downstream
experiments had an absorbance260/280 ratio exceeding 2.00,and ribonucleic acid concentrations were diluted to 50 to
100 ng/μl prior to cDNA synthesis. cDNA was synthesized
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). Quantitative
polymerase chain reaction (qPCR) was carried out using a
StepOnePlus Real-Time PCR system (Applied Biosystems).
SYBR Green Master Mix reagent (Life Technologies, Grand
Island, NY, USA) was used for a fluorescent probe ac-
cording to the manufacturer’s guidelines. Primers for
Col7a1 consisted of 5′-TGGTAACAACCTCGGCA-
CAG-3′ (forward) and 5′-AAGTCTGGGCCTCACGAA
TG-3′ (reverse). Primers for Tsg-6 consisted of 5′-GCTCA
CGGATGGGGATTCAA-3′ (forward) and 5′-TTGTAG
GTTGCGAGACGACC-3′ (reverse). Primers for Cxcr4
consisted of 5′-CGGCTGTAGAGCGAGTGTTG-3′
(forward) and 5′-CATCAACTGCCCAGAAGGGG-3′
(reverse). Primers for GAPDH consisted of 5′-CCAG
CAAGGACACTGAGCAA-3′ (forward) and 5′-CCCTA
GGCCCCTCCTGTTAT-3′ (reverse). All qPCR reactions
were carried out in triplicate in a total reaction volume of
20 μl (8 μl RNase-free water, 10 μl of 2× SYBR Green
Master Mix, 0.5 μl each forward and reverse primers, and
1 μl cDNA). Reaction times and temperatures for all qPCR
reactions were as follows: initial 10-minute hold for en-
zyme activation (95°C) followed by 40 cycles of 15-second
denaturing (95°C), 30-second annealing (53°C), and
30-second extension (60°C). qPCR data were analyzed using
ExpressionSuite Software (Applied Biosystems) according
to the comparative cycle threshold (2–ΔΔCT) method. PCR
for purposes of gel electrophoresis was carried out using
AmpliTaq DNA polymerase reagents (Applied Biosystems)
according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assays
Sandwich enzyme-linked immunosorbent assays (ELISAs)
for detection of secreted C7 were performed using an anti-
mouse C7 ELISA kit (CUSABIO, Wuhan, China) according
to the manufacturer’s protocol. For each experiment, 2 ×
105 cells were split evenly into two flasks and incubated in
αMEM. Treated cells were exposed to 15 ng/ml TGFβ +30
ng/ml TNFα. At 48 hours, medium was removed and fro-
zen at –80°C until ELISAs were carried out.
In vitro chemotaxis assay
In vitro chemotaxis assays were performed using a 12-
well chemotaxis chamber (Neuro Probe Inc., Gaithers-
burg, MD, USA). GFP-expressing cells were lifted using
0.25% trypsin–ethylenediamine tetraacetic acid and
allowed to settle in a 1 ml suspension of αMEM for 1
hour prior to chemotaxis experiments. Cells were sus-
pended at a concentration of 5 × 105/ml, such that ap-
proximately 50,000 cells were placed into the 100 μl top
compartments. Bottom wells were filled with αMEM+
varying concentrations of SDF-1α. For blocking controls,
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a potent CXCR4 receptor antagonist. Following the as-
says, the nonmigrated surfaces of the 25 × 80 mm poly-
carbonate filters were washed in phosphate-buffered
saline, and the migrated surfaces were fixed in 10% neu-
tral buffered formalin. Cells were visualized under a
fluorescent microscope using a FITC filter and counted
three times per well at 200× (total magnification).Flow cytometry
Flow cytometry experiments were carried out on a FACS-
Canto system (BD Biosciences, San Jose, CA, USA) and an-
alyzed using FlowJo (Tree Star Inc., Ashland, OR, USA)
and FCX Express 4 Research Edition (De Novo Software,
Los Angeles, CA, USA). Prior to extracellular staining, cells
were lifted using 0.25% trypsin–ethylenediamine tetraacetic
acid and allowed to settle in a 1 ml suspension of αMEM
for 1 hour. Extracellular CXCR4 was detected using 1 μg/
100 μl APC-tagged rat monoclonal anti-mouse CXCR4
antibody with 1 μg/100 μl APC-tagged rat IgG2b-κ anti-
body used as an isotype control (BD Biosciences). All extra-
cellular staining included an initial Fc block using a purified
rat monoclonal anti-mouse CD16/CD32 antibody at 0.5
μg/100 μl (eBioscience, San Diego, CA, USA).Data analysis
Differences between measured variables were conducted
using a two-tailed Student’s t test, with P <0.05 considered
significant.Results
Effect of preconditioning duration on Col7a1 and Tsg-6
mRNA expression
To investigate whether murine MSCs are capable of upreg-
ulating transcription of Col7a1 and Tsg-6, cells were treated
with 10 ng/ml TGFβ +20 ng/ml TNFα in αMEM, incu-
bated for 24, 48, or 72 hours, and compared with untreated
controls. Following the designated incubation periods,
RNA was extracted, reverse transcribed, and subjected to
qPCR. The observed relative quantification values across
two experiments are displayed in Figure 1b. As shown, in-
creased transcription of both Col7a1 and Tsg-6 was ob-
served across all three time points, demonstrating that
MSCs can upregulate transcription of these two genes via
exposure to cytokine preconditioning. With regards to a
time-dependent effect of preconditioning, Col7a1 tran-
scription was significantly higher at 48 hours (5.7-fold in-
crease ±0.20) relative to 24 and 72 hours, while Col7a1
transcription at 72 hours was also significantly higher than
at 24 hours. Tsg-6 transcription was highest at 24 hours
(4.5-fold increase ±0.79) and significantly higher than at
72 hours but not at 48 hours.Effect of preconditioning dosage on Col7a1 and Tsg-6
mRNA expression
To determine whether a dose–response effect exists with
regards to strength of cytokine exposure and subsequent
changes in Col7a1 and Tsg-6 transcription, cells were
treated for 48 hours in the presence of varying cytokine
concentrations and compared with untreated controls
(Figure 1c). Cells treated with 15 ng/ml TGFβ +30 ng/
ml TNFα showed the greatest increase in both Col7a1
(8.4-fold increase ±0.12) and Tsg-6 (3.8-fold increase ±0.19)
transcription, and these changes were significantly higher
than in the other three treatment groups. There was no sig-
nificant difference in Col7a1 transcription between the 5
ng/ml TGFβ +10 ng/ml TNFα and the 10 ng/ml TGFβ +20
ng/ml TNFα groups, while a significant increase and de-
crease was seen below and above the 15 ng/ml TGFβ +30
ng/ml TNFα group, respectively. These results, taken to-
gether with those shown in Figure 1b, demonstrate that
treating cells with 15 ng/ml TGFβ +30 ng/ml TNFα for 48
hours elicits the greatest fold increase in Col7a1 tran-
scription, and this protocol was used in all subsequent
experiments.
Preconditioning effects after removal of cytokines
To determine how persistent the preconditioning effects are
with regards to Col7a1 and Tsg-6 mRNA expression, cells
were treated with 15 ng/ml TGFβ +30 ng/ml TNFα for 48
hours, washed with phosphate-buffered saline, and placed in
αMEM for 48 hours as a cytokine-free environment.
Figure 1d shows that after being removed from the precon-
ditioning environment for 48 hours, there was still a twofold
increase (±0.17) in Col7a1 mRNA levels relative to un-
treated cells. Interestingly,Tsg-6 mRNA expression appeared
to be downregulated once removed from the precondition-
ing environment. These results suggest that while Col7a1
upregulation can be maintained for at least 48 hours follow-
ing removal of cytokine stimuli, the effects on Tsg-6 upregu-
lation are more transient and revert to a downregulated
state within 48 hours of cytokine removal. It should be
noted that, as seen in Figure 1b, both Col7a1 and Tsg-6
transcription could be held in the upregulated state for at
least 72 hours as long as the preconditioning environment
was present, but, as the results in Figure 1d demonstrate,
once cells were removed from the preconditioning environ-
ment the upregulatory effects on Tsg-6 transcription appear
to be reversed in the absence of extracellular cytokines.
Effects of preconditioning on type VII collagen protein
secretion
To demonstrate whether the transcriptional upregulation
of Col7a1 seen following cytokine preconditioning corre-
sponds to increased secretion of C7, a sandwich ELISA
was performed to compare the culture medium of un-
treated cells with cells treated for 48 hours with 15 ng/ml
Figure 1 Cytokine preconditioning induces simultaneous upregulation of Col7a1 and Tsg-6 mRNA expression in mesenchymal stem cells.
(a) Untreated mesenchymal stem cells (MSCs) exhibit detectable baseline expression of Col7a1, Tsg-6, and Cxcr4. (b) MSCs were treated with 10 ng/ml
transforming growth factor beta (TGFβ) +20 ng/ml tumor necrosis factor alpha (TNFα) for 24, 48, or 72 hours. Quantitative polymerase chain reaction
(qPCR) was performed for Col7a1 and Tsg-6 expression in treated groups relative to untreated MSCs. (c) MSCs were treated across concentration gradients
of TGFβ and TNFα for 48 hours. qPCR was performed for Col7a1 and Tsg-6 expression in treated groups relative to untreated MSCs. (d) MSCs were treated
with 15 ng/ml TGFβ +30 ng/ml TNFα for 48 hours. Cells were transferred to an alpha minimum essential medium-only environment for a subsequent 48
hours, after which qPCR was performed for Col7a1 and Tsg-6 expression in treated groups relative to untreated MSCs. All qPCR values in (b) to (d) were
normalized against endogenous glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. All qPCR experiments were run in triplicate and across
two experimental groups per condition. Data presented as mean ± standard deviation. *P <0.05 by Student’s t test.
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period, 2 × 105 cells were split evenly into two flasks for
each of the two experimental and control groups. As
shown in Figure 2, treated cells showed a significantly
higher level of C7 secretion relative to untreated cells and
an approximate 70% increase above baseline (14.4 ± 1.6 vs.
8.3 ± 0.17 ng/ml; P <0.005).
Simultaneous upregulation of Cxcr4, Col7a1, and Tsg-6
The importance of the CXCR4/SDF-1α chemokine axis
within the context of stem cell transplantation and migra-
tion to injured tissue has been demonstrated across several
disease models [28-30]. Having shown simultaneous upreg-
ulation of Col7a1 and Tsg-6 mRNA expression, we next
aimed to incorporate Cxcr4 upregulation as part of the pre-
conditioning protocol. To achieve this, cells were treated
with 15 ng/ml TGFβ +30 ng/ml TNFα for 48 hours as de-
scribed above, after which 30 ng/ml SDF-1α was intro-
duced for 1 hour. Figure 3a demonstrates that, under this
protocol, upregulation of all three genes could be achieved
simultaneously, and that Cxcr4 mRNA levels were 2.2-fold
higher than in untreated cells. While Col7a1 expression
here was not significantly different from that in cells treated
with 15 ng/ml TGFβ +30 ng/ml TNFα for 48 hourswithout the 1-hour SDF-1α treatment (Figure 1c), Tsg-6 ex-
pression was significantly less (3.8-fold vs. 2.0-fold, P <0.05)
in the presence of SDF-1α treatment, although still twofold
higher than in untreated cells and comparable with levels
seen in the other treatment gradients shown in Figure 1c.
To assess the physiologically relevant utility of this proto-
col – that is, whether preconditioning could also upregulate
cell surface CXCR4 protein – treated cells were examined
using flow cytometry (Figure 3b) and were found to exhibit
a 28.5% increase in the cell surface CXCR4 signal relative
to untreated cells. Next, a chemotaxis chamber was used to
determine whether this increase in cell surface CXCR4
would result in improved migratory capabilities toward an
SDF-1α gradient. As displayed in Figure 3c, treated cells
showed a significantly greater migratory response toward
SDF-1α gradients of 60 and 90 ng/ml, but not 30 ng/ml.
Importantly, it is worth noting that, similar to the report by
Potapova and colleagues [40], our attempts at characteriz-
ing cell surface CXCR4 expression of cells brought directly
from monolayer conditions to flow cytometry experiments
generally yielded an undetectable CXCR4 signal (data not
shown), while cells that were subjected to a 1-hour reset-
tling period in a cell suspension environment during SDF-
1α treatment yielded the results described herein.
Figure 2 Cytokine preconditioning results in increased type VII
collagen protein secretion. Mesenchymal stem cells (MSCs) were
treated with 15 ng/ml transforming growth factor beta +30 ng/ml
tumor necrosis factor alpha for 48 hours. Following this incubation
period, culture medium was extracted and subjected to sandwich
enzyme-linked immunosorbent assay (ELISA) analysis. Culture
medium from treated groups was compared with that of untreated
MSCs. ELISA experiments were carried out across two biological
groups per condition (105 cells per group). Data presented as
mean ± standard deviation. *P <0.005 by Student’s t test. C7, type
VII collagen protein.
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The results presented here demonstrate for the first time,
to the best of our knowledge, upregulation of Col7a1
mRNA and C7 expression in MSCs using an exogenous
preconditioning protocol. Additionally, we present the
feasibility of a three-tiered preconditioning model to im-
prove the efficacy of transplanted MSCs in the context of
RDEB therapy. This model incorporates: an improved
chemotactic response by MSCs toward an SDF-1α gradient
(via Cxcr4 upregulation and increased cell surface CXCR4
expression) as a surrogate for homing to injured tissue; an
increased functional role for MSCs once present in tissue
(via increased Col7a1 and C7 expression); and a more po-
tent immunosuppressive arsenal and wound-healing re-
sponse of MSCs via upregulation of Tsg-6 expression.
Given the demonstrated ability of implementing only three
cytokines (TGFβ, TNFα, and SDF-1α) to induce a simultan-
eous upregulation in Col7a1, Tsg-6, and Cxcr4, we believe
that this protocol represents a very straightforward yet po-
tentially high-yield approach for improving the efficacy of
MSCs in the context of RDEB transplantation, either as a
supportive role within HCT or as a potential standalone
therapy. We also demonstrate the feasibility and broad
applicability of preconditioning protocols, whereby trans-
planted cells are rendered more functionally suitablein vitro for the specific disease of interest prior to
transplantation.
To appreciate the physiologic significance of a sixfold to
eightfold increase in Col7a1 expression by MSCs, it is ne-
cessary to compare expression levels across various cell
types. We previously provided a characterization of baseline
Col7a1 expression across murine bone marrow and stem
cell lineages, and found MSCs to exhibit an approximate
15-fold greater expression profile than whole bone marrow
cells as well as CD150+/48– and Lin– subsets of the bone
marrow population [27]. Based on these previous character-
izations, a sixfold to eightfold increase in baseline Col7a1
expression of MSCs, as demonstrated throughout the
present study, would place them at about one-third the ex-
pression level of multipotent adult progenitor cells, and at
18% of the relative Col7a1 expression found in wild-type
skin. At the protein level, Alexeev and colleagues found that
intradermal injections of wild-type MSCs into a mouse
model of RDEB resulted in C7 expression at 15% that of
wild-type levels [26]. Incorporating the approximate 70%
increase in C7 secretion we observed under our current
preconditioning regimen, this would bring C7 levels toward
the 30% of the amount of wild-type C7 that is believed to
be adequate for preventing blistering in the context of
RDEB [41]. Thus, it is reasonable to suggest that precondi-
tioned MSCs would be capable of supplying the necessary
C7 to facilitate significant restoration of the DEJ following
transplantation.
To address the transiency of preconditioning effects
observed in the present study, we demonstrate that
Col7a1 expression can be held in the upregulated state
for at least 72 hours in the presence of cytokines. We
also demonstrate that an upregulated state of Col7a1 ex-
pression can be held for at least 48 hours following re-
moval of cytokine stimuli, albeit at lower levels than
seen in the presence of preconditioning. A legitimate
question thus arises regarding whether the increase in
Col7a1 would be too transient to establish any signifi-
cant change following transplantation. Here we wish to
emphasize the Trojan horse aspect of preconditioning
with regards to delivery of C7 to cutaneous sites, where
the increase in Col7a1 expression seen pre-transplant
would provide an initial restorative benefit, after which
MSCs would be expected to resume baseline C7 secre-
tion, which Alexeev and colleagues have shown to be ap-
proximately 15% that of wild-type DEJ [26]. Based on
our current results, the transition from an upregulated
state to a baseline state would be expected to occur after
at least 48 hours, and perhaps even longer depending on
the cytokine milieu present in RDEB skin [42]. Import-
antly, RDEB cells have been shown to exhibit increased
expression of TGFβ and COL7A1 [38], albeit dysfunc-
tional COL7A1, and thus it is logical that preconditioned
wild-type MSCs would continue to display elevated C7
Figure 3 Addition of SDF-1α to the preconditioning protocol induces simultaneous upregulation of Col7a1, Tsg-6, and Cxcr4 mRNA
expression. Mesenchymal stem cells (MSCs) were treated with 15 ng/ml transforming growth factor beta +30 ng/ml tumor necrosis factor alpha for 48
hours. At 47 hours, cells were exposed to 30 ng/ml stromal cell-derived factor 1-alpha (SDF-1α) for 1 hour. (a) Quantitative polymerase chain reaction
(qPCR) was performed for Col7a1, Tsg-6, and Cxcr4 expression in treated cells relative to untreated MSCs. qPCR values were normalized against endogenous
glyceraldehyde 3-phosphate dehydrogenase expression, and experiments were run in triplicate and across two experimental groups. (b) Flow cytometry
was performed to assess cell surface CXCR4 expression in treated versus untreated cells. (c) Chemotaxis assay results of treated versus untreated cells:
50,000 GFP-expressing cells were placed in each top well, while increasing SDF-1α gradients were used in the bottom wells. For blocking controls, treated
and untreated cells were incubated in presence of 100 μg/ml AMD3100 for 1 hour and exposed to a 90 ng/ml SDF-1α concentration gradient during the
assay. Experiments were run in duplicate. (d) Representative fluorescent microscopy images of the chemotaxis membrane following the assay. Data
presented as mean ± standard deviation. *P <0.05 by Student’s t test.
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TGFβ in vivo. Cytokine preconditioning of MSCs may
thus provide an added initial influx of C7 to cutaneous
sites, followed by a probably lessened but continual se-
cretion of C7. Future in vivo studies will be necessary to
examine whether systemic infusions of preconditioned
MSCs are capable of bringing C7 levels at the DEJ in
RDEB skin to levels sufficient for long-term cutaneous
repair.
It is worth highlighting the downregulation in Tsg-6
expression (3.8-fold vs. 2.0-fold) we observed when go-
ing from the 48-hour treatment of 15 ng/ml TGFβ +30
ng/ml TNFα (Figure 1c) to the addition of 30 ng/ml
SDF-1α for 1 hour (Figure 3a). It is conceivable that
SDF-1α, a chemokine implicated in the migration of
proinflammatory cells, may exert feedback inhibition on
anti-inflammatory signals such as TSG-6. Although both
Cxcr4 and Tsg-6 genes could simultaneously be brought
to the upregulated state, it appears that in the context of
a pre-transplantation protocol, the addition of SDF-1αto the preconditioning regimen would be at the expense
of partial loss of Tsg-6 expression. Given the improved
migrational performance seen with the addition of SDF-
1α, however, increased cell surface CXCR4 protein at the
expense of partially dampened Tsg-6 expression may
be worthwhile during the transplantation window, as
wounded cutaneous sites (for example, RDEB skin)
experienced by MSCs following transplantation would
provide an additional stimulus for prolonged Tsg-6 up-
regulation in vivo [31].
Furthermore, it is worth noting that although we were
able to observe a 2.2-fold increase in Cxcr4 expression
using the protocol described by Jones and colleagues [30],
we were unable to attain the degree of upregulation de-
scribed in their original findings (approximately fivefold).
A probable explanation for this difference is the source of
cells used, as human fetal MSCs were used by Jones and
colleagues while MSCs from mice aged 2 to 3 weeks were
used in the present study. Potapova and colleagues also
described an internalization of CXCR4 protein in response
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port an increase in cell surface CXCR4. However, the dif-
ference in responses is probably due to the vastly greater
SDF-1α concentrations used by Potapova and colleagues
(1 μg/ml vs. 30 ng/ml in the present study) and the differ-
ing effects of such concentrations on sensitization of cell
surface CXCR4 and shunting of the chemokine receptor
toward intracellular pools.
Recently, the work by Lin and colleagues has provided an
exciting demonstration of the clinical possibilities afforded
by manipulating the CXCR4/SDF-1α axis [43]. The admin-
istration of AMD3100 (a CXCR4 antagonist) and low-dose
tacrolimus resulted in liberation of bone marrow cells into
the circulation and improved wound healing at cutaneous
sites. While these results could have implications across
many clinical contexts, they also highlight the importance
of SDF-1α expression at wounded tissue sites and its role in
recruiting CXCR4-expressing bone marrow-derived cells,
as blocking SDF-1α using intradermal antibody injections
resulted in a loss of wound healing benefits. Looking be-
yond the CXCR4/SDF-1α axis, future attempts at exogen-
ously upregulating the CCR10 expression of MSCs prior to
transplantation may also prove to be a valuable approach,
as the CCR10/CCL27 axis has been implicated in improved
targeting of MSCs to cutaneous sites [42].
Transforming growth factor beta: more than just fibrosis
Like many cytokines, TGFβ has numerous attributed roles
in a variety of contexts. One of its most widely known
functions is as an anti-inflammatory and profibrotic
stimulus. Specifically, TGFβ released from macrophages
during an inflammatory response is known to promote
myofibroblast differentiation as part of the wound repair
and profibrotic process [31]. Additionally, culturing MSCs
in the presence of TGFβ has previously been shown to up-
regulate levels of α-smooth muscle actin [44], a marker at-
tributed to but not specific for myofibroblasts. If these
two properties are loosely connected, an association be-
tween TGFβ-treated MSCs adopting a myofibroblast-like
phenotype and a subsequent progression to a profibrotic
state may be drawn. However, increased α-smooth muscle
actin and associated rates of contractile activity are not
limited to fibrotic processes, and in fact are thought to be
an important mechanism in tissues that are actively
employing new extracellular matrix and/or attempting to
increase tissue strain [45]. While this has been demon-
strated in settings such as ligament repair [46], it may also
be involved at the DEJ in RDEB skin following incorpor-
ation of new C7 into the tissue architecture. Additionally,
preconditioning of MSCs using a cytokine cocktail that in-
cluded TGFβ was shown to be beneficial in restoring car-
diac function in a murine model of myocardial infarction
[47]. Previous reports of TGFβ-mediated increases of α-
smooth muscle actin and contractility in MSCs shouldthus not be used synonymously with a profibrotic process,
but instead should be looked at as a mechanism that can
occur in a variety of physiologic contexts. Of course, fu-
ture in vivo studies are needed to assess whether the con-
textual benefits of TGFβ preconditioning outweigh any
profibrotic changes that may accumulate prior to the
MSCs reverting back to the baseline state, where they
have previously been shown to have a beneficial effect on
the cutaneous environment in the RDEB phenotype [26].
Prolonged TGFβ signaling has also been implicated in
the context-dependent procarcinogenic transformation of
MSCs in certain cancer pathologies. For example, MSCs
cultured for 21 days in the presence of TGFβ as part of
tumor-conditioned medium were shown to increase ex-
pression of procarcinogenic factors [48]. Culturing MSCs
with tumor-conditioned medium for 16 days was also
shown to promote transition of the cells into tumor-
associated fibroblasts, which are associated with various
protumorigenic and epithelial-to-mesenchymal functions
[49]. Conversely, inhibition of TGFβ signaling in MSCs
exposed to tumor-secreted factors led to increased proin-
flammatory responses of MSCs to the tumor microenvir-
onment [50]. Thus, while TGFβ is certainly an important
cytokine for interactions between dysplasias and local
MSCs, its role is probably context dependent and cell line
dependent, and is thought to serve both tumor suppres-
sive and pro-epithelial-to-mesenchymal functions in dif-
ferent settings [51].
Patients with RDEB experience drastically increased
rates of squamous cell carcinoma (SCC), and this process
may involve the known increased TGFβ signaling found
in RDEB SCC skin [38]. However, since TGFβ is also ele-
vated in non-SCC RDEB skin, Knaup and colleagues re-
flect that the increased TGFβ in this setting may also be
an attempt to call for increased COL7A1 expression rather
than as part of a strict carcinogenic process. They also
point out that increased TGFβ by itself is unlikely to cause
malignant consequences, while concomitant mutations
and stage of tumorigenesis during exposure to elevated
TGFβ signaling seems to be more significant [38,52]. Of
course, cellular therapies for RDEB involving any aspect of
TGFβ and other cytokine signaling should seriously con-
sider whether an added risk for SCC may develop. Given
that the involved pathways probably require prolonged
time intervals and multifaceted signals to develop, the
48-hour preconditioning protocol presently used that
involves isolated TGFβ and TNFα signals would not be
expected to increase risk for SCC following transplant-
ation. Additionally, the chronic inflammatory state and
dysfunctional cutaneous environment associated with
RDEB are thought to largely drive the increased risk for
SCC [38], and the presented therapy would seek to limit
chronic inflammation via stabilization of the DEJ and thus
reduce overall cancer progression. However, it is unclear
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introduction of cytokine-treated MSCs into RDEB pa-
tients, specifically those in which epithelial dysplasia has
previously been established. Future studies will be neces-
sary to elucidate whether this therapeutic approach may
elevate risk for SCC in recipients with or without prior
epithelial dysplasia.
Emerging potential of preconditioning
The concept of preconditioning MSCs prior to transplant
has up to this point been largely focused on the settings of
myocardial infarction (see review by Li and colleagues
[53]) and ischemic stroke (see review by Yu and colleagues
[54]). Although the degree of transplanted cell death in
these ischemic environments has represented a barrier to
their therapeutic potential, in vitro hypoxic precondition-
ing has been used as a method to enhance MSC graft sur-
vival post transplant [55]. In addition to promoting cell
survival, preconditioning in ischemic disease has also been
shown to prove functionally useful. For instance, in vitro
treatment of MSCs using oxidative stress signals led to up-
regulation of various cardiogenic factors [56], and this
method may show promise for future myocardial infarc-
tion infusion protocols. Herrmann and colleagues found
that preconditioning with TGFα led to an enhanced cardi-
oprotective role for MSCs [57], and MSCs preconditioned
with a cytokine cocktail, including TGFβ, were shown to
be beneficial for restoring cardiac function in a model of
myocardial infarction [47]. Furthermore, enabling MSCs
to be better migrators toward injured tissue is another ap-
plication of preconditioning, as shown previously by Jones
and colleagues via upregulation of CXCR4 expression in a
model of osteogenesis imperfecta [30]. Several aspects of
MSC functionality – whether graft survival, migration, or
disease modification – have thus been demonstrated to
improve under preconditioning protocols. Considering
that our overall knowledge of MSCs is still in its relative
infancy, even more so is our understanding of their poten-
tial applications toward therapy. As researchers continue
to target MSCs as candidates for cell-based therapies in
the future, the concept of preconditioning is something
that should be considered for investigation. Since some
form of in vitro expansion is required as an intermediate
step between harvesting and transplant due to the relative
low frequency of MSCs at extraction sites, the addition of
preconditioning protocols does not require extensive time
or effort, and the advantages gained from this application
could have extraordinary potential.
Clinical strategies for approaching recessive dystrophic
epidermolysis bullosa therapy
There are several promising approaches on the horizon
for attaining improved outcomes in RDEB patients. First,
there exist considerable efforts to further modify stem celltransplantation techniques that have previously been
shown to ameliorate the RDEB phenotype [15]. While the
exact mechanism as to how HCT is capable of producing
these results has yet to be fully elucidated, it is thought
that nonhematopoietic cells within the graft, including
MSCs, may be largely responsible [17]. This hypothesis is
supported in part by findings that bone marrow-derived
MSCs can give rise to epithelial progenitors that promote
regeneration and restoration of C7 within grafted C7-null
skin [58], and also by evidence that MSCs are directly cap-
able of restoring partial DEJ function in RDEB skin [26].
The ability to exogenously upregulate COL7A1 and C7 ex-
pression in MSCs in the pre-transplant period, as demon-
strated here, thus supports a larger and more defined role
for MSCs within the overall transplantation approach to-
ward RDEB therapy in the future. The use of stem cell
transplantation is not without its hazards, however, as the
intensive immunosuppressive regimen required for such a
procedure is an additional stressor to RDEB patients. An
additional benefit of expanding the role for MSCs in this
context may thus allow for a less intensive immunomye-
loablative protocol in the pre-transplant and post-
transplant periods by taking advantage of the inherent im-
munosuppressive properties of MSCs. With regards to
how this preconditioning method may impact screening
and harvesting protocols for allogeneic transplants, exist-
ing methods such as haplotyping, extraction, expansion,
and fluorescence-activated cell sorting would largely go
unchanged (see review by Ikebe and Suzuki [59] for over-
view of MSC collection and expansion protocols). Of
course, the incorporation of a preconditioning regimen
would require an additional step within the expansion
phase of cell preparation, but would otherwise not be ex-
pected to complicate existing protocols. Whether add-
itional safety concerns would be introduced during the
infusion window by way of applying exogenous cytokines
during cell culture expansions is something that will need
to be addressed in future in vivo animal and human
studies.
Second, the use of intradermal fibroblast injections as a
method for treating RDEB has transitioned into the setting
of human studies [10,60]. These methods have been shown
to improve wound healing in ulcerated areas of patients’
skin and to promote increased presence of C7 at the DEJ.
The current understanding of how injected fibroblasts exert
these beneficial effects is via upregulating endogenous
production of mutant C7 [61]. Thus, while these techniques
may prove useful in RDEB patients with some degree of
functional baseline C7 production, they may not attain
benefits in patients with complete absence of COL7A1 ex-
pression. Taking into consideration that fibroblasts have
previously been shown to upregulate COL7A1 expression
via in vitro cytokine treatments [33,34], the idea of precon-
ditioning cells prior to transplantation, as demonstrated in
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that warrants investigation in other transplantation
modalities such as intradermal fibroblast injections. As
with other therapeutic strategies in the context of
RDEB, however, intradermal fibroblast injections are
not without their limitations. The need for multiple in-
jections across different areas of skin and the questions
surrounding the half-life of efficacy for each injection
are variables that will need to be addressed in the future,
and that also highlight the benefits of transitioning to
systemic allogeneic fibroblast infusions as a potential re-
lated therapeutic modality.
Third, there has been considerable attention placed
on the idea of using C7 as a therapeutic strategy for
treating RDEB patients. This approach began with the
use of intradermal recombinant C7 injections [12,13],
which were shown to reverse the RDEB phenotype in
grafted skin as well as in an RDEB mouse model. Given
that the use of intradermal injections could be limited
by the diffusing capacity of C7 and the large surface area
of RDEB lesions, as well as the inability to reach muco-
sal lesions (for example, of the esophagus), the use of
systemic intravenous infusions of soluble C7 have now
come into focus [14]. Initial reports of this approach
demonstrated an incorporation of injected C7 into the
DEJ of RDEB skin grafts and improved dermal–epider-
mal integrity. While it is likely that this approach will
one day translate into improved outcomes in human
RDEB patients, the use of systemic C7 injections, much
like stem cell transplantation and intradermal fibroblast
injections, is also not without its limitations. For in-
stance, although C7 exhibits a relatively long half-life of
several months [62], in the absence of an endogenous
producer of functional C7 it is conceivable that an
individual with RDEB would require lifelong rounds of
injection for a sustainable therapy to manifest itself.
Additionally, it will be important to determine whether
certain recipients may be at risk for developing
immunity against injected C7. Recently, it has been
demonstrated that anti-C7 antibodies may be relatively
common among RDEB patients and that most may be
nonpathogenic [63]. However, in the event that an anti-
body response does occur following injections, this
approach may also warrant some degree of immunosup-
pressive modulation.
Each of the strategies for approaching RDEB therapy
described above have several advantages and numerous
obstacles. The effect of preconditioning on cells prior to
transplant, specifically in terms of COL7A1 upregulation
as described here, would not only be beneficial in the
context of bone marrow and cord blood transplantations
for RDEB therapy, but could also prove valuable with
regards to stromal cell (mesenchymal and fibroblast)
therapies.Conclusions
To our knowledge, we demonstrate for the first time an up-
regulation of Col7a1 mRNA and C7 expression in MSCs
using an exogenous preconditioning protocol. By using a
regimen of TGFβ, TNFα, and SDF-1α, MSCs are capable of
simultaneously upregulating Col7a1, Tsg-6, and Cxcr4 ex-
pression. This three-tiered approach renders MSCs more
functionally equipped for treating RDEB via increased C7
secretion, more potent immunosuppressants and wound-
healers via upregulated Tsg-6, and better migrators toward
injured tissue via enhanced cell surface CXCR4 expression.
HCT has previously been shown to ameliorate the RDEB
phenotype in pediatric patients, and this response is
thought to be partially attributable to MSCs within the graft
[17]. Additionally, MSCs have been shown to restore C7 at
the DEJ in a mouse model of RDEB [26]. These previous
findings, along with our current presented data, suggest
that preconditioned MSCs represent a feasible method-
ology for approaching systemic RDEB therapy. Ongoing
and future in vivo studies and clinical trials involving allo-
geneic transplants for RDEB may benefit from analyzing
the utility of such preconditioning protocols, and whether
they provide an improvement over the effects seen with un-
conditioned cells.
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